Navigation Links
Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
Date:2/7/2008

CRANBURY, N.J., Feb. 7 /PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at BIO CEO & Investor Conference 2008 in New York, NY on Monday, February 11, 2008 at 12:30 pm (Eastern Standard Time) at the Waldorf-Astoria Hotel.

The presentation will be webcast live and may be accessed by visiting Amicus' website at http://www.amicustherapeutics.com. A replay of the webcast will also be available on the Company's website until February 25, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company has completed Phase 1 clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as,
'/>"/>

SOURCE Amicus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... The first product launch from start-up ... to robotics. What sets Droidles completely apart from other ... allows them to communicate, share code with each other ... , “The invention is the system,” said Hurley Research ... life of their own, both physically and on the ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The prestigious ... of Congress was recently awarded to Juliana Hillis and ... MA, for their project, “From an Egg, Everything: America’s ... 3,000 final entries for the National History Day program ... 300 historians and educators in Washington, D.C. , The ...
(Date:7/29/2014)... July 29, 2014 White papers ... and cloud based eClinical technologies, have been published by ... These follow a long line of white papers by ... including Life Science Leader, Pharmaceutical Online, and OpenHealthNews. , ... a paper by CTO Marc Desgrousilliers, 'The Five ...
(Date:7/29/2014)... July 29, 2014 ... (LBS) zur Erfassung biologischer Daten in Verbindung ... und patentiert. Das LBS nimmt gleichzeitig mehrere ... des Patienten und sucht erhöhte biologische Aktivitäten ... Potenzial, die Entdeckung und Entwicklung neuer Medikamente ...
Breaking Biology Technology:Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4
... only Web-based solution for managing compliance and regulated content throughout ... , SAN DIEGO, June 22 Drug ... Virtify, Inc. , the market leader in enterprise ... upcoming release of its Virtx integrated software suite, an end-to-end, ...
... alternative to Singulair and Zicam - The ALCAT Test , ... FDA knocked the wind out of asthmatics by requesting the ... drug, to upgrade their warning against psychotic side effects. Further ... also last week announced warnings that the drug may cause ...
... , , SINGAPORE, June 22 Globally, the largest ... achieve a reduction in CO2 emissions by 8.0 percent between 2008 ... 5.75 percent bio-fuels of all transportation fuel by December 2010 and ... market, it is witnessing rapid growth in terms of both new ...
Cached Biology Technology:Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies 2Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies 3Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies 4Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies 5Knocking the Wind Out of Asthmatics: Help from Hippocrates 2Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 2Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 3Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 4
(Date:7/28/2014)... of Medicine have pinpointed a mechanism in part of the ... blood, linking it to both type 1 and type 2 ... of Proceedings of the National Academies of Sciences . ... located in a part of the hypothalamus known as the ... that control glucose levels in the blood," said lead author ...
(Date:7/28/2014)... the top 10 U.S. cities that have seen an ... as frequent road closures, overwhelmed storm drains and compromised ... NOAA technical report. , This nuisance flooding, caused by ... coasts, between 300 and 925 percent since the 1960s. ... Frequency Changes around the United States, also finds Annapolis ...
(Date:7/28/2014)... has identified areas of the Earth that are high ... , Europe is particularly vulnerable, as it has the ... cent, of any continent in ,refugia, areas of ... conditions remain relatively constant during times of great environmental ... mostly in Scandinavia and Scotland. , The biggest ...
Breaking Biology News(10 mins):Glucose 'control switch' in the brain key to both types of diabetes 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Study finds Europe's habitat and wildlife is vulnerable to climate change 2
... TORONTO, ON A team of University of Toronto chemists ... quantum biology, observing quantum mechanics at work in photosynthesis in ... speculation that nature may be using quantum mechanical practices," says ... published this week in Nature . "Our latest ...
... that glaciers in the Himalayan mountains are thinning is ... examine and quantify the causes. Lawrence Berkeley National Laboratory ... of the most commonly blamed culpritgreenhouse gases, such as ... be causing the melting. Menon and her collaborators found ...
... For Immediate Release A team of scientists at ... on novel binding sites for an enzyme used by the ... discovery lays the foundation for the development of a new ... strains of the disease, and slow the evolution of drug ...
Cached Biology News:Scientists find quantum mechanics at work in photosynthesis 2Black carbon a significant factor in melting of Himalayan glaciers 2Black carbon a significant factor in melting of Himalayan glaciers 3Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 2Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 3Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 4Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 5
Sheep polyclonal to Streptomycin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule: Streptomycin conjugated to BSA....
Rabbit polyclonal to MAL ( Abpromise for all tested applications). entrezGeneID: 4118 SwissProtID: P21145...
Glutamate Receptor 5/1a...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Biology Products: